atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced the appointments of Scott Braunstein and Laurent Fischer as directors to its board.
Braunstein previously served as chief operating officer of Pacira Pharmaceuticals and as a portfolio manager of JP Morgan’s global healthcare fund, having started out as a practising physician.
Fischer has held chairman, chief executive and other leadership roles at the likes of CTI Biopharma, Tobira Therapeutics, Jennerex, RXCentric, MedVantx, and Dupont Pharmaceuticals.
atai chairman Christian Angermayer highlighted the pair’s “remarkable achievements in the biopharmaceutical sector and comprehensive understanding of drug development and commercialization”.
They “will be instrumental to our board and management team as we advance into later-stage clinical trials,” he added.
Both also currently hold chief executive roles at other companies, with Braunstein at Marinus Pharmaceuticals and Fischer heading up Adverum Biotechnologies.
Their appointments come as Jason Camm steps down from the board, atai added, following four years of “invaluable contributions”.